News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

March 17, 2025

Lipidor announces all patients enrolled in ongoing Phase III study

STOCKHOLM, Sweden, 17th March 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been randomized. Lipidor now expects study results in the last week of May 2025. The main purpose of…

October 4, 2018

Lipidor: First Patient In for Phase III trial of Calcipotriol Spray, a new high-comfort, high-control anti-psoriasis spray

Stockholm, Sweden 4 October: Psoriasis is a chronic disease affecting 2-4% of the world’s population. A new anti-psoriasis spray now in a…

September 3, 2018

Lipidor: New CEO at helm as company gears up for IPO

Ola Holmlund begins as Lipidor’s new CEO on September 1. With a powerful track record in Business Development and Strategic Sales, Holmlund…

August 23, 2018

Lipidor gets go-ahead for Phase III Clinical Study of new Calcipotriol Spray treatment for psoriasis

India’s CDSCO (Central Drugs Standard Control Organization) has approved Phase III Trials of a new topical anti-psoriatic spray developed by Swedish company…

April 10, 2018

Lipidor AB strengthens its board and aims for an IPO in 2019

Lipidor AB, a pharmaceutical company developing innovative products based on its proprietary AKVANO® technology, announces today its plan to list the company…